New CML Treatment Shows Promise, But Standard Therapy Endures
The ASC4FIRST trial explores asciminib for chronic myeloid leukaemia, but experts question its design and outcomes, suggesting imatinib remains the preferred first-line therapy.
The ASC4FIRST trial explores asciminib for chronic myeloid leukaemia, but experts question its design and outcomes, suggesting imatinib remains the preferred first-line therapy.
Jairo Noreña, MD, endocrinology fellow at Stanford University, discusses an investigational therapy for the potential treatment of congenital hyperinsulinism.
Marilyn Tan, MD, Chief of the Endocrine Clinic at Stanford Healthcare, provides an overview of hypoglycemia.
BRAF V600 mutations are the epitome of targeted therapy. However, not much is known about non-V600 mutations. Using the new data infrastructure of the Swiss…
Clinical Trials That Changed the Life of Cancer Patients: Insights from the CEO of EORTC, Dr. Denis Lacombe / cancer, cancer care, Cancer research, clinical
A Type II variation application has been submitted to the EMA for subcutaneous daratumumab plus VRd in newly diagnosed multiple myeloma.
This study focused on whether preexisting cardiovascular disease increased the odds of developing cardiovascular adverse events during Bruton tyrosine kina
Online resource for healthcare professionals, providing information, news & support relating to AML
The US House of Representatives has recently passed a new legislation that allows patients with cancer and other critical illnesses to receive their medication by…
This event was organised by the European Organisation for Research and Treatment of Cancer (EORTC), the Breast International group (BIG), & the EU Health Pol…
Jacqueline Brown, MD, discusses the current role of enfortumab vedotin plus pembrolizumab in bladder cancer and tips for early AE management.